Faster* Delivery with OPDIVO Qvantig™
OPDIVO Qvantig is FDA approved across most adult, solid-tumor OPDIVO® indications, excluding those in combination with ipilimumab.
*Faster delivery compared with 30-minute infusion of OPDIVO IV. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.
Welcome
Here’s where you can explore the breadth of indications and range of treatment options OPDIVO (nivolumab) and OPDIVO-based combinations offer. Find efficacy and safety data, dosing schedules, and resources for both you and your patients.
Explore the latest data, approvals, and updates
Subcutaneous Injection Treatment Option
OPDIVO QvantigTM (nivolumab + hyaluronidase-nvhy) is now approved as a 3-5 minute subcutaneous injection.
NOW APPROVED
1L Unresectable or Metastatic HCC Option
OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
NEW DATA
Explore the Latest Data in Advanced RCC Treatment
NEW DATA
Discover the latest data in non-small cell lung cancer treatment